NCT02143986 Glycosylated Ferritin in Macrophagic Activation Syndromes
| NCT ID | NCT02143986 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brugmann University Hospital |
| Condition | Still's Disease, Adult-Onset |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2014-05 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2014-05 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated \[1, 2\] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but is rarely less than 20% \[3 , 4\] . Percentage of glycosylated ferritin below 20% have been described in patients with adult Still's disease and haemophagocytosis lymphohistiocytic syndromes (HLH). The glycosylated ferritin has been included in the diagnostic criteria for Still's disease in adults. A cut-off of less than 20 % has a sensitivity and specificity of 72 and 69 % respectively , and 35 and 94 % when combined with a total ferritin level greater than 5 times normal value. This parameter was also suggested to be a more specific marker to confirm a diagnosis of HLH than a high ferritin level ( \> 500μg / L). However, several limitations of this parameter were highlighted, some conditions making its interpretation difficult : particularly in cases of major hepatic cytolysis and severe sepsis (miliary tuberculosis, lymphoma and disease Adult Still). It is not always possible to distinguish severe sepsis, HLH syndrome and Still's disease. A fine analysis of various glycoforms components of ferritin could be used to distinguish different subgroups of patients. Few data are available on the mechanism of secretion and glycosylation of ferritin, but the investigators assume that the glycosylation patterns of ferritin may vary between different disease states and reflect distinct underlying pathophysiological mechanisms.
Eligibility Criteria
Inclusion Criteria: * Suspicion of sepsis, macrophagic activation syndrome, Still's disease or hyperferritinemia (malignant disease, hepatic cytolysis) Exclusion Criteria: * Normal ferritin level
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02143986 clinical trial?
This trial is open to participants of all sexes, up to 85 Years, studying Still's Disease, Adult-Onset. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02143986 currently recruiting?
Yes, NCT02143986 is actively recruiting participants. Contact the research team at francis.corazza@ulb.ac.be for enrollment information.
Where is the NCT02143986 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT02143986 clinical trial?
NCT02143986 is sponsored by Brugmann University Hospital. The trial plans to enroll 60 participants.